



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

PT

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/522,716	03/10/2000	Edward P. Cohen	10464A	6035

7590 07/02/2004

EXAMINER

ATT: IP PROSECUTION
HOWREY, SIMON, ARNOLD & WHITE, LLP
1299 PENNSYLVANIA AVENUE, N.W.
BOX NO. 34
WASHINGTON, DC 20004-2402

YAEN, CHRISTOPHER H

ART UNIT	PAPER NUMBER
1642	

DATE MAILED: 07/02/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action	Application No.	Applicant(s)
	09/522,716	COHEN, EDWARD P.
	Examiner	Art Unit
	Christopher H Yaen	1642

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 26 April 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

PERIOD FOR REPLY [check either a) or b)]

a) The period for reply expires ____ months from the mailing date of the final rejection.
 b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.
 ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. A Notice of Appeal was filed on _____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. The proposed amendment(s) will not be entered because:
 - (a) they raise new issues that would require further consideration and/or search (see NOTE below);
 - (b) they raise the issue of new matter (see Note below);
 - (c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 - (d) they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: ____.

3. Applicant's reply has overcome the following rejection(s): _____.
4. Newly proposed or amended claim(s) ____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____.

Claim(s) objected to: 43 and 46.


Claim(s) rejected: 26,41,42,44,45 and 47-53.

Claim(s) withdrawn from consideration: _____.

8. The drawing correction filed on ____ is a) approved or b) disapproved by the Examiner.

9. Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____.

10. Other: _____.


GARY B. NICKOL, PH.D.
PRIMARY EXAMINER

Christopher Yaen
 Art Unit 1642

Continuation of 5. does NOT place the application in condition for allowance because: applicant's arguments concerning the rejections under 35 USC 102(b), 102(e), and 112, 1st paragraph enablement are not found persuasive. With regard to the 102(b) and 102(e) rejections, applicant argues that the references do not anticipate because each and every limitation of the claims have not been taught, specifically the transfection of "genomic DNA". Applicant points to page 30 and 31 for a specific definition of the term "genomic DNA" however, none was found. Therefore because the term has not been adequately defined by the specification and because Eisenbach et al teach the instantly claimed method, the invention is still anticipated. With regard to the 112, 1st paragraph rejection for lacking an enabling disclosure concerning the prevention of a tumor, applicant argues that the specification enables the method and specifically points to example 15. Applicant's arguments have been carefully considered but are not deemed persuasive to overcome the rejection of record. Prevention of a disease requires there be an understanding of the population with which treatment is to be administered, in other words, there must be a treatment or administration prior to the inception of the disease. This type of pre-treatment requires knowledge of which members within that population would require administration. In the example cited by the applicant, the tumor was already present and therefore the population was already defined before the administration of the composition. The irrefutable link between antecedent drug and subsequent knowledge of the prevention of the disease is the essence of a valid preventive agent. Further, a preventive administration also must assume that the therapeutic will be safe and tolerable for anyone susceptible to the disease. The specification has not provided any of these findings and therefore the scope of prevention has not been enabled by the instant specification.